UNITED THERAPEUTICS Corp

UTHR - CIK 0001082554

Market cap$23.10 B

Rank#558

SEC filings4,203

UNITED THERAPEUTICS Corp trades as UTHR and has a market capitalization of $23.10 B, making it the #558 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $3.18B, up 10.6% from the prior year and net income of $1.33B. This page tracks UNITED THERAPEUTICS Corp through 4,203 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$3.18BFY 2025

Net income (latest FY)$1.33BFY 2025

Operating cash flow (latest FY)$1.56BFY 2025

Total assets (latest FY)$7.88BFY 2025

Gross margin87.9%latest FY

Net margin41.9%latest FY

Financial performance

Over the last 9 fiscal years UNITED THERAPEUTICS Corp's revenue grew from $1.60B to $3.18B, a compound annual growth rate of 7.9%. Net profit margin expanded from 28.2% to 41.9% over the same period - every figure below comes from the company's audited annual filings.

UTHR annual revenueView details

Key statistics

Market cap: $23.10 B
Share price (derived)market cap / shares outstanding: $544.10
P/E ratio (trailing FY): 17.3
EPS (diluted)FY 2025: $27.86
Shares outstandingas of 2026-04-29: 0.04B
Total equityas of 2026-03-31: $5.90B
Return on equity: 22.6%
Cash & equivalentsas of 2026-03-31: $1.28B

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-22
Insider trade	4	2026-05-22
Insider sale notice	144	2026-05-21
Insider trade	4	2026-05-21
Insider trade	4	2026-05-21
Insider trade	4	2026-05-20
Insider trade	4	2026-05-19
Insider trade	4	2026-05-19

Browse the full filing history (4,203 filings)

Recent press releases

United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 20262026-05-18
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026 – United Therapeutics Investor Relations
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 20262026-05-17
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026 – United Therapeutics Investor Relations
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial2026-05-15
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial – United Therapeutics Investor Relations
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference2026-05-12
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 20262026-05-11
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026

Similar companies

The largest companies sharing UNITED THERAPEUTICS Corp's SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T UTHR vs LLY

JNJJohnson & Johnson$573.98 B UTHR vs JNJ

ABBVAbbVie Inc.$399.47 B UTHR vs ABBV

MRKMerck & Co., Inc.$293.16 B UTHR vs MRK

AZNAstraZeneca PLC$286.27 B UTHR vs AZN

Frequently asked questions

What is UNITED THERAPEUTICS Corp's market cap?

UNITED THERAPEUTICS Corp (UTHR) has a market capitalization of $23.10 B as of 2026-06-10, ranking #558 among US-listed companies.

How much revenue does UNITED THERAPEUTICS Corp make?

UNITED THERAPEUTICS Corp reported revenue of $3.18B for fiscal year 2025, an increase of 10.6% year over year.

Is UNITED THERAPEUTICS Corp profitable?

Yes. UNITED THERAPEUTICS Corp reported net income of $1.33B in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.